Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.